Innovent Biologics, Takeda form strategic collaboration to develop next generation IO and ADC cancer therapies including IBI363, IBI343 (HK$86.90, 0.00)
Exelixis to present results from subgroup analysis of CABINET trial of CABOMETYX at ESMO ($39.25, 0.00)
FDA approves sBLA for Adynovate, confirms fulfillment of all post-marketing requirements (¥4198.0000, 0)
Nabla Bio (private) announces second collaboration with Takeda (4502.JP); milestones could exceed $1B (5:00ET) (¥4228.0000, 0)
Hutchmed to present results from phase III part of FRUSІCA-2 trial for renal cell carcinoma on 17-Oct at ESMO Congress (HK$23.52, -1.22)
Takeda Pharmaceutical discontinues cell therapy efforts, to recognize ¥58.0B impairment loss in Q2
White House says the latest pharmaceutical tariffs do not apply to countries with negotiated trade deals -- wires
Trump announces next round of tariffs effective 1-Oct, signs executive order on TikTok deal:
Trump says pharmaceutical products imported into US will be hit with 100% tariff starting 1-Oct - Truth Social post
Heidelberg Pharma advances to Cohort 9 in Phase I/IIa trial of HDP-101 in multiple myeloma (€3.16, -0.29)
Powered by FactSet Research Systems Inc.